Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Somavaratan (VRS-317) monthly dosing in adult growth hormone deficiency
2015-002072-24Phase 2Completed
- Sponsor
- Versartis, Inc.
- Start
- Aug 2015
- Modality
- Fc-Fusion Proteins → Carrier/Scaffold Proteins → Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of somavaratan in growth hormone deficiency (GHD), sponsored by Versartis, Inc. Primary endpoint: IGF-I SDS levels within therapeutic range after first dose. Started Aug 2015; status: completed.
02
Drugs
somavaratan
03
Conditions
growth hormone deficiency (GHD)
Beyond the preview
Go deeper on 2015-002072-24.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2015-002072-24.